Psilocybin beat placebo in the first NHS-funded trial

Almost every psilocybin trial that has made headlines was paid for by a company with a psilocybin product. That is not a scandal, and it is a reason to want the experiment run by somebody else.

A trial published in Nature Medicine is the first publicly funded trial of its kind delivering psilocybin treatment within an NHS setting in England, paid for by the National Institute for Health and Care Research instead of by industry.

It recruited 60 participants with treatment resistant depression, gave half of them a single 25mg dose and half a genuine placebo, and supported both groups the same way. Depression scores fell substantially further in the psilocybin group.

The trial was not designed to prove that. Understanding why is most of the story.

What treatment-resistant depression means

Depression, also called major depressive disorder or clinical depression, can cause severe symptoms that affect how you feel, think, and handle daily activities, such as sleeping, eating, or working. It is one of the most common mental disorders in the United States.

For most people, one of the standard treatments works. For a substantial minority none of them do, and that is the group this trial recruited.

The entry bar was specific. Eligible participants met the standard diagnostic criteria for major depressive disorder and had an inadequate response to at least two antidepressant treatments, or at least one antidepressant plus at least one psychotherapy.

The National Institute of Mental Health describes this as an open problem, saying it is supporting research to develop and test therapies for people with treatment-resistant depression who don’t improve after trying multiple treatment options.

How the psilocybin trial worked

A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one NHS site in England. Sixty participants were randomized (1:1), balanced by age, sex and prior psilocybin exposure.

Participants received 25-mg psilocybin or placebo with preparation, dosing support and integration. Preparation is the sessions beforehand, integration the sessions afterward that work through what happened. Both arms got all of it. Only the capsule differed.

The placebo matters more here than usual. Half received a 25mg dose of psilocybin; half received a true placebo, meaning no psilocybin at all. Some trials in this field use a tiny dose instead, which risks nobody being fooled about which group they are in.

A participant described the dosing session as emotionally intense, including a vivid experience of seeing deceased family members, followed by exhaustion, and later said it helped them understand their depression better, though they described it as difficult and painful.

What the depression scores did

The adjusted between-group difference at week 3 on the Montgomery-Asberg Depression Rating Scale (MADRS) was -10.41, favoring psilocybin, which was sustained at week 6. That scale is the standard clinician-rated measure of depression, and roughly ten points is a large move on it.

The proportions are easier to picture. 43 percent of the psilocybin group met the threshold for treatment response at three weeks, rising to 50 percent by six weeks, compared with three percent of the placebo group throughout.

For full remission, meaning the score fell below the level that counts as depression: 40 percent of the psilocybin group met remission threshold at three weeks, compared with three percent on placebo, and this held at six weeks.

Professor James Rucker, the lead investigator at the Institute of Psychiatry, Psychology & Neuroscience, keeps the claim narrow: “Here, we show that a randomised trial design of psilocybin compared to a true placebo was feasible in participants who had often failed many different types of treatment.”

Why the trial design limits what psilocybin proves

Read the primary outcomes and the framing changes. Primary outcomes were recruitment, retention and estimation of the MADRS variance.

That is a trial asking three questions: can we find these patients, will they stay, and how widely do their scores scatter? The third one is the reason such trials exist, because you cannot size a definitive trial without knowing how much the outcome varies.

The depression difference is a by-product of that exercise, estimated from 60 people at one site over six weeks. It is a large effect, measured honestly, from a sample too small to be the last word. The authors say so directly: findings support a future confirmatory trial.

Sixty people is also small enough that the double-blind is worth doubting. A 25mg dose of psilocybin is noticeable, and participants and staff can often guess which arm they are in, which inflates any outcome that depends on a rating.

What the trial says about psilocybin safety

In total, 123 and 164 nonserious adverse events occurred in the placebo and psilocybin arms, respectively, mostly mild and resolving by trial end.

Four serious adverse events were recorded, three in the psilocybin arm and one in the placebo arm, none judged related to psilocybin itself. Retention was almost complete: 59 of 60 participants completed the MADRS at all follow-up visits.

One practical finding sits underneath all of that. Catherine Bird, the senior clinical trials manager on the study, notes what moving out of hospital demonstrated: “The move showed us that psilocybin can be administered safely outside a hospital setting.”

What this means if you have depression

Nothing changes today. Psilocybin remains a controlled drug, this was a supervised research setting, and taking it alone is neither legal in most places nor anything this trial speaks to.

What has changed is who produced the evidence. Professor Ben Carter, the trial’s lead methodologist, puts it as replication: “These are exciting findings that replicate industry funded studies showing the considerable potential of Psychedelics as a class of medication.”

An independent replication of a commercially funded result is worth more than another result from the company. Rucker’s own framing is the right size: “Publicly funded clinical trials are an important part of the jigsaw of evidence needed for a new intervention to find its place in the real world.”

A jigsaw piece is what this is.

A neighboring piece arrived in the same journal weeks later. Dronabinol, a pharmaceutical form of the main psychoactive compound in cannabis, reduced PTSD nightmares in a placebo-controlled trial, with a safety signal that needs resolving.